Latest & greatest articles for ipratropium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ipratropium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ipratropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ipratropium

1. Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial

Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial Short-acting β2 -agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short-acting anticholinergics is clinically more effective care compared to treatment with β2 -agonists (...) alone in patients with hypercapnic AECOPD.The objective was to evaluate whether combining ipratropium bromide (IB) to terbutaline reduces hospital and intensive care unit (ICU) admission rates compared to terbutaline alone in AECOPD hypercapnic patients.In this double-blind controlled trial, patients who were admitted to the ED for AECOPD requiring noninvasive ventilation (NIV) were randomized to receive either 5 mg of nebulized terbutaline combined to 0.5 mg of IB (terbutaline/IB group, n = 115

2018 EvidenceUpdates

2. Ipratropium

Ipratropium Top results for ipratropium - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ipratropium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Transient anisocoria in a patient treated with nebulized ipratropium bromide (Full text)

Transient anisocoria in a patient treated with nebulized ipratropium bromide We present a case report of a 44-year old female patient with complicated pneumonia who developed anisocoria after treatment with inhaled ipratropium bromide. Discontinuation of ipratropium bromide treatment led to complete resolution of anisocoria.A 44-year old female patient was admitted to the Department of Pulmonology due to high body temperature (40.0 °C), coughing and general weakness. After a general examination (...) and tests the patient was diagnosed with right-sided pneumonia. Since spirometry test showed signs of bronchial obstruction, pulmonologist indicated inhalation therapy with ipratropium bromide. Soon after ipratropium bromide therapy was initiated, the patient noticed enlarged left pupil and stated that some aerosol reached her left eye during the inhalation therapy. After consulting neurology and monitoring neurological signs, ipratropium bromide treatment was discontinued. Twenty-four hours after

2017 American journal of ophthalmology case reports PubMed

6. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. (Full text)

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Tiotropium and ipratropium bromide are both recognised treatments in the management of people with stable chronic obstructive pulmonary disease (COPD). There are new studies which have compared tiotropium with ipratropium bromide, making an update necessary.To compare the relative effects of tiotropium to ipratropium bromide on markers of quality of life, exacerbations, symptoms, lung function and serious adverse (...) events in patients with COPD using available randomised controlled trial (RCT) data.We identified RCTs from the Cochrane Airways Group Specialised Register of trials (CAGR) and ClinicalTrials.gov up to August 2015.We included parallel group RCTs of 12 weeks duration or longer comparing treatment with tiotropium with ipratropium bromide for patients with stable COPD.Two review authors independently assessed studies for inclusion and then extracted data on study quality and outcome results. We

2015 Cochrane PubMed

7. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. (PubMed)

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Tiotropium and ipratropium bromide are both recognised treatments in the management of people with stable chronic obstructive pulmonary disease (COPD). There are new studies which have compared tiotropium with ipratropium bromide, making an update necessary.To compare the relative effects of tiotropium to ipratropium bromide on markers of quality of life, exacerbations, symptoms, lung function and serious adverse (...) events in patients with COPD using available randomised controlled trial (RCT) data.We identified RCTs from the Cochrane Airways Group Specialised Register of trials (CAGR) and ClinicalTrials.gov up to November 2012.We included parallel group RCTs of 12 weeks duration or longer comparing treatment with tiotropium with ipratropium bromide for patients with stable COPD.Two review authors independently assessed studies for inclusion and then extracted data on study quality and outcome results. We

2013 Cochrane

8. Intranasal ipratropium bromide for the common cold. (PubMed)

Intranasal ipratropium bromide for the common cold. The common cold is one of the most common illnesses in humans and constitutes an economic burden both in terms of productivity and expenditure for treatment. There is no proven cure for the common cold and symptomatic relief is the mainstay of treatment. The use of intranasal ipratropium bromide (IB) has been addressed in several studies and might prove an effective treatment for the common cold.To determine the effect of IB versus placebo

2013 Cochrane

9. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Tiotropium appears to help improve objective lung function test measures, reduce

2012 Health Technology Assessment (HTA) Database.

10. Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness

Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could (...) -commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 29 Aug 2012 CONTEXT

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Nebulized Ipratropium for Asthma Attack

Nebulized Ipratropium for Asthma Attack Nebulized Ipratropium for Asthma Attack – TheNNTTheNNT Nebulized Ipratropium Given During an Asthma Attack 11 for prevented hospitalization In Summary, for those who received the ipratropium: Benefits in NNT 90.9% saw no benefit from adding ipraptropium during an asthma attack 9.1% were helped by preventing hospitalization 1 in 11 were helped (preventing hospitalization) Harms in NNT 0% were harmed by drug side effects None were harmed (serious side (...) effects) View As: NNT % Source: Efficacy Endpoints: Need for hospitalization Harm Endpoints: Medication side effects Narrative: Acute asthma exacerbation is responsible for an estimated 1.6 million emergency department visits and over 440,000 hospital admissions per year . The cornerstone of management remains aerosolized, short acting, β2-agonists and systemic corticosteroids . Anticholinergic agents such as ipratropium bromide, are effective bronchodilators, but comparative studies suggest

2012 theNNT

12. Intranasal ipratropium bromide for the common cold. (PubMed)

Intranasal ipratropium bromide for the common cold. The common cold is one of the most common illnesses in humans and constitutes an economic burden both in terms of productivity and expenditure for treatment. There is no proven cure for the common cold and symptomatic relief is the mainstay of treatment. The use of intranasal ipratropium bromide (IB) has been addressed in several studies and might prove an effective treatment for the common cold.To determine the effect of IB versus placebo

2011 Cochrane

13. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray

Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Drug Approval Package: Combivent Respimat (ipratropium bromide and albuterol) NDA #021747 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray Company: Boehringer Ingelheim Pharmaceutical, Inc. Application No.: 021747 Approval Date: 10/07/2011 Persons with disabilities having problems accessing the PDF files below may

2011 FDA - Drug Approval Package

14. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD (Full text)

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD Gani R, Griffin J, Kelly S, Rutten-van Molken M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of tiotropium, ipratropium, and salmeterol, for the treatment of chronic obstructive pulmonary disease. The authors concluded that tiotropium was a cost-effective alternative to ipratropium and salmeterol, and switching patients from ipratropium and salmeterol to tiotropium led to considerable cost savings

2010 NHS Economic Evaluation Database. PubMed

15. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness

Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness Pohar R, Nkansah E Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pohar R, Nkansah E. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions In two RCTs, patients with moderate to severe COPD who were

2009 Health Technology Assessment (HTA) Database.

16. Drugs - Ipratropium Bromide (Atrovent)

Drugs - Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute (...) asthma or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive

2007 Joint Royal Colleges Ambulance Liaison Committee

17. A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction (Full text)

A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A smoking cessation programme plus inhaled ipratropium improved survival in asymptomatic airway obstruction Article Text Therapeutics A smoking cessation programme plus inhaled

2006 Evidence-Based Medicine (Requires free registration) PubMed

18. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. (PubMed)

Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a condition associated with high morbidity, mortality and cost to the community. Patients often report symptomatic improvement with long acting beta-2 agonists (LABAs) and anticholinergic bronchodilator medications, both of which are recommended in COPD guidelines. These medications have different mechanisms of action and therefore (...) theoretically could have an additive effect when combined. As these medications are prescribed in COPD as long term therapy, it is important to assemble reliable evidence on their relative and additive effects.To compare the relative efficacy and safety of regular long term use (at least four weeks) of ipratropium bromide and LABA in patients with stable COPD. Comparisons were made between single agents and in combination versus LABAs alone.We searched the Cochrane Airways Group Specialised Register

2006 Cochrane

19. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. (PubMed)

Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a condition associated with high morbidity, mortality and cost to the community. Patients often report symptomatic improvement with short-acting beta-2 agonists (SABA) and anticholinergic bronchodilator medications, and both are recommended in COPD guidelines. These medications have different mechanisms of action and therefore could have (...) an additive effect when combined.To compare the relative efficacy and safety of regular long term use (at least four weeks) of ipratropium bromide and short- acting beta-2 agonist therapy in patients with stable COPD.The Cochrane Airways Group Specialised Register of Trials was searched. Bibliographies were checked to identify relevant cross-references. Drug companies were contacted for relevant trial data. The searches are current to August 2005.All randomised controlled trials comparing at least 4 weeks

2006 Cochrane

20. Ipratropium Bromide (Atrovent)

Ipratropium Bromide (Atrovent) Ipratropium Bromide (Atrovent) IPR Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Nebules containing ipratropium bromide 250 micrograms in 1ml or 500 micrograms in 2ml. ACTIONS 1.Ipratropium bromide is an antimuscarinic bronchodilator drug. It may provide short term relief in acute asthma, but beta 2 agonists (such as salbutamol) generally work more quickly. Ipratropium should be considered in acute severe or life threatening asthma or in cases of acute asthma (...) or COPD which fail to improve with standard therapy (including salbutamol). 2. Ipratropium is considered of greater bene?t in: a. children suffering acute asthma. b. adults suffering with COPD. DOSAGE AND ADMINISTRATION CAUTIONS Ipratropium should be used with care in patients with: • glaucoma (protect the eyes from mist). • pregnancy and breastfeeding. INDICATIONS Acute severe or life threatening asthma (to be given concurrent with ?rst dose of salbutamol). Acute asthma unresponsive to salbutamol

2006 Joint Royal Colleges Ambulance Liaison Committee